-
Innovation Ranking
NewInnovation Ranking – Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that develops therapeutics in the area of male health and diagnostic products. It is developing a drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH) and early-stage prostate cancer. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes N9icAlert test to determine smoking status; and TobacAlert home test to determine a person’s level of exposure to tobacco products,...
-
Product Insights
Benign Prostatic Hyperplasia – Drugs In Development, 2023
Global Markets Direct’s, ‘Benign Prostatic Hyperplasia - Drugs In Development, 2023’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fexapotide Triflutate in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fexapotide Triflutate in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fexapotide Triflutate in Prostate CancerDrug Details:NX-1207 (fexapotide triflutate) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCP-776 in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SCP-776 in Acute Ischemic Stroke Drug Details:SCP-776 is under development for the treatment of congestive heart...
-
Company Profile
Nymox Pharmaceutical Corp – Company Profile
Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that develops therapeutics in the area of male health and diagnostic products. It is developing a drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH) and early-stage prostate cancer. The company markets diagnostic products for measuring tobacco product exposure and for the diagnosis of Alzheimer’s disease. Its diagnostic product portfolio includes N9icAlert test to determine smoking status; and TobacAlert home test to determine a person’s level of exposure to tobacco products,...
Add to Basket -
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – fexapotide triflutate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fexapotide triflutate Drug Details NX-1207 (fexapotide triflutate) is under development for the treatment of...
-
Product Insights
Benign Prostatic Hyperplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Benign Prostatic Hyperplasia (BPH) include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. The Benign Prostatic Hyperplasia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer’s Disease Drugs Development Report Overview Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. Buy the Full Report for More Insights on the Alzheimer’s Disease Drugs in Development Report, Download a Free Sample The Alzheimer’s Disease Drugs in Development market research report provides an overview of the...